JP2014509637A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509637A5
JP2014509637A5 JP2014501722A JP2014501722A JP2014509637A5 JP 2014509637 A5 JP2014509637 A5 JP 2014509637A5 JP 2014501722 A JP2014501722 A JP 2014501722A JP 2014501722 A JP2014501722 A JP 2014501722A JP 2014509637 A5 JP2014509637 A5 JP 2014509637A5
Authority
JP
Japan
Prior art keywords
compound
formula
medicament
composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014501722A
Other languages
English (en)
Japanese (ja)
Other versions
JP5826374B2 (ja
JP2014509637A (ja
Filing date
Publication date
Priority claimed from GBGB1105659.5A external-priority patent/GB201105659D0/en
Application filed filed Critical
Publication of JP2014509637A publication Critical patent/JP2014509637A/ja
Publication of JP2014509637A5 publication Critical patent/JP2014509637A5/ja
Application granted granted Critical
Publication of JP5826374B2 publication Critical patent/JP5826374B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014501722A 2011-04-01 2012-03-29 チエノ［２，３−ｄ］ピリミジン誘導体及び不整脈を処置するためのそれらの使用 Expired - Fee Related JP5826374B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1105659.5 2011-04-01
GBGB1105659.5A GB201105659D0 (en) 2011-04-01 2011-04-01 Compounds
PCT/GB2012/050710 WO2012131379A1 (en) 2011-04-01 2012-03-29 Thieno [2, 3 -d] pyrimidine derivatives and their use to treat arrhythmia

Publications (3)

Publication Number Publication Date
JP2014509637A JP2014509637A (ja) 2014-04-21
JP2014509637A5 true JP2014509637A5 (enExample) 2015-07-23
JP5826374B2 JP5826374B2 (ja) 2015-12-02

Family

ID=44071904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014501722A Expired - Fee Related JP5826374B2 (ja) 2011-04-01 2012-03-29 チエノ［２，３−ｄ］ピリミジン誘導体及び不整脈を処置するためのそれらの使用

Country Status (42)

Country Link
US (1) US9249155B2 (enExample)
EP (1) EP2694518B1 (enExample)
JP (1) JP5826374B2 (enExample)
KR (1) KR20140023332A (enExample)
CN (1) CN103492392B (enExample)
AP (1) AP2013007198A0 (enExample)
AR (1) AR088735A1 (enExample)
AU (1) AU2012235882B2 (enExample)
BR (1) BR112013025236A2 (enExample)
CA (1) CA2831493A1 (enExample)
CL (1) CL2013002789A1 (enExample)
CO (1) CO6801756A2 (enExample)
CR (1) CR20130488A (enExample)
CU (1) CU24173B1 (enExample)
CY (1) CY1117025T1 (enExample)
DK (1) DK2694518T3 (enExample)
EA (1) EA201301111A1 (enExample)
EC (1) ECSP13012988A (enExample)
ES (1) ES2558563T3 (enExample)
GB (1) GB201105659D0 (enExample)
GT (1) GT201300225A (enExample)
HR (1) HRP20151340T1 (enExample)
HU (1) HUE028438T2 (enExample)
IL (1) IL228555A0 (enExample)
MA (1) MA35064B1 (enExample)
ME (1) ME02314B (enExample)
MX (1) MX335937B (enExample)
NI (1) NI201300100A (enExample)
PE (1) PE20141021A1 (enExample)
PH (1) PH12013501952A1 (enExample)
PL (1) PL2694518T3 (enExample)
PT (1) PT2694518E (enExample)
RS (1) RS54458B1 (enExample)
RU (1) RU2013148627A (enExample)
SG (1) SG193578A1 (enExample)
SI (1) SI2694518T1 (enExample)
SM (1) SMT201500322B (enExample)
TN (1) TN2013000377A1 (enExample)
TW (1) TWI516265B (enExample)
UA (1) UA110131C2 (enExample)
WO (1) WO2012131379A1 (enExample)
ZA (1) ZA201307085B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922858A4 (en) * 2012-11-20 2016-06-15 Univ Mcgill THIENOPYRIMIDININHIBITORS OF FARNESYL AND / OR GERANYL GERANYL PYROPHOSPHATE SYNTHASE
CN109311868B (zh) 2015-12-22 2022-04-01 尚医治疗有限责任公司 用于治疗癌症和炎性疾病的化合物
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
BR112019027640A2 (pt) 2017-06-21 2020-07-07 SHY Therapeutics LLC composto, método para testar a capacidade de um ou mais compostos, método para inibir a função de ras, método para inibir a função de rho, método para inibir a função de rac, composição farmacêutica
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH317906A (de) 1953-09-16 1956-12-15 Sandoz Ag Verfahren zur Herstellung von 1-Amino-4-oxyanthrachinonsulfonsäuren
AU521790B2 (en) 1977-05-23 1982-04-29 Ici Australia Limited Process for eradication of ticks
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DD226893A1 (de) 1981-12-15 1985-09-04 Ralf Boehm Verfahren zur herstellung von arylaminosubstituierten thieno 2,3-d pyrimidinen
IL112567A (en) 1994-02-10 2000-02-29 Wyeth John & Brother Ltd Substituted quinolines their preparation and pharmaceutical compositions containing them
IL112568A0 (en) 1994-02-10 1995-05-26 Wyeth John & Brother Ltd Substituted quinolines, their preparation and pharmaceutical compositions containing them
IL112569A (en) 1994-02-10 1999-12-22 Wyeth John & Brother Ltd Pharmaceutical compositions comprising cyclohexylamine derivatives certain such novel compounds and their preparation
IL112566A (en) 1994-02-10 2000-10-31 Wyeth John & Brother Ltd Substituted quinolinones and pharmaceutical compositions containing them
EP0846119B1 (en) 1995-08-17 2002-11-13 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use as endothelin antagonists
AU713573B2 (en) 1996-07-26 1999-12-02 Nissan Chemical Industries Ltd. Chroman derivatives
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
RU2116309C1 (ru) 1997-02-13 1998-07-27 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 4-[(бензо-2,1,3-тиадиазолил-4)амино]-5,6,7,8-тетрагидробензотиено [2,3-d]пиримидин, обладающий противогельминтной активностью при ларвальном альвеолярном эхинококкозе
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
JP2002517385A (ja) 1998-06-05 2002-06-18 イカゲン インク． カリウムチャネル阻害剤
WO2000012492A1 (en) 1998-09-01 2000-03-09 Nissan Chemical Industries, Ltd. Benzoxazine derivatives
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2001021610A1 (en) 1999-09-17 2001-03-29 Nissan Chemical Industries, Ltd. Benzopyran derivative
WO2001021609A1 (en) 1999-09-24 2001-03-29 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
AU7453900A (en) 1999-10-05 2001-05-10 Nissan Chemical Industries Ltd. 4-oxybenzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
CA2393756A1 (en) 1999-12-21 2001-06-28 Aimee D. Reed Potassium channel inhibitors
DE60132606T2 (de) 2000-09-20 2009-02-19 Merck & Co., Inc. Isochinolinone als kalium-kanal-inhibitoren
DE10054481A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002062343A2 (en) 2001-02-02 2002-08-15 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
DE10104802A1 (de) 2001-02-02 2002-08-08 Merck Patent Gmbh Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (1)
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
CA2450541A1 (en) 2001-06-25 2003-01-03 Nissan Chemical Industries, Ltd. Substituted benzopyran derivatives against arrhythmia
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
DK1641803T3 (da) 2003-06-11 2009-06-29 Xention Ltd Thienopyrimidinderivater som kaliumkanalinhibitorer
ZA200600197B (en) * 2003-07-02 2007-06-27 Vertex Pharma Pyrimidines useful as modulators of voltage-gated ion channels
JP2007517793A (ja) 2004-01-06 2007-07-05 大正製薬株式会社 環状アミノ基によって置換されたチエノピリミジン及びチエノピリジン誘導体
JP2008505084A (ja) 2004-06-29 2008-02-21 アムゲン インコーポレイティッド フラノピリミジン
EP1879899B1 (en) 2004-12-09 2010-08-04 Xention Limited Thienopyridine derivatives as potassium channel inhibitors
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US20080108611A1 (en) 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
JP2009539988A (ja) 2006-06-12 2009-11-19 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルの調節因子として有用なチエノピリミジン
DE102009039893B4 (de) 2009-09-03 2012-03-29 Bundesanstalt für Materialforschung und -Prüfung (BAM) Verwendung eines Brennstoffs in einem selbstunterhaltenden pulsierenden Sauerstoff-Brennstoff-Verbrennungsprozess

Similar Documents

Publication Publication Date Title
JP2013032389A5 (enExample)
JP2013518107A5 (enExample)
JP2014507446A5 (enExample)
JP2013509429A5 (enExample)
JP2012255026A5 (enExample)
JP2013542247A5 (enExample)
JP2015078230A5 (enExample)
JP2017524735A5 (enExample)
JP2016534063A5 (enExample)
JP2014521735A5 (enExample)
EP4643945A3 (en) Neuroactive steroids and methods of use thereof
MY165117A (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
JP2017514910A5 (enExample)
JP2015516419A5 (enExample)
JP2016510326A5 (enExample)
JP2016522254A5 (enExample)
JP2015509075A5 (enExample)
JP2010521516A5 (enExample)
PH12015501945A1 (en) Formulations of organic compounds
JP2016532632A5 (enExample)
JP2014509637A5 (enExample)
JP2016515550A5 (enExample)
JP2013513607A5 (enExample)
JP2014148552A5 (enExample)
JP2011515406A5 (enExample)